Tags : Enters

Amazon Enters into Fitness Space with the Launch of Halo

Shots: Amazon launches the Halo fitness band and a subscription service by the same name. The smart band combines a suite of AI-powered health tool with an innovative and stylish wrist band Halo band and subscription service unlock an array of health metrics, including activity, sleep, body fat, and tone of voice analysis, to determine […]Read More

Celltrion Enters the Next Phase of Development for its Antiviral

Shots: The transition to the second phase of development follows the completion of the first phase of securing 300 different types of Abs targeting the antigen last month. The library of Ab was developed utilizing the blood of recovered patients in Korea Celltrion will initiate the screening of Ab to find the most effective one […]Read More

Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to

Shots: Orionis to receive research funding, convertible notes, clinical milestones along with royalties while Novartis gets access to Orionis’ Allo-Glue technology platform for designing novel therapies like protein degraders across multiple therapeutic areas The collaboration will combine Novartis’ expertise in drug discovery and development with Orionis’ innovative technologies for identifying and prioritizing new targets at […]Read More

MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for

Shots: MSD to supply Keytruda (pembrolizumab) to I-Mab to utilize it in clinical studies in combination with its TJC4. The companies will collaborate to evaluate PK/PD & preliminary efficacy of dual regimen for multiple cancer indications in a P-I study The collaboration will further explore the therapeutic potential of combination therapy, TJC4 with Keytruda across […]Read More

Vertex Signs an Access Agreement with Scottish Government for Orkambi

Shots: The access agreement allows patients with eligible cystic fibrosis to access Orkambi and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in Scotland Vertex will collect real-world data on the combination therapies which will support future regulatory submission to the Scottish Medicines Consortium (SMC) following the 5yrs. access agreement Orkambi is a combination therapy used to […]Read More

Hansoh Enters into a Collaboration with Atomwise for AI-Based Drug

Shots: Atomwise to receive technology access fees, option exercise fees, royalties, and income-based on sublicensing or sale of assets leading to a total deal value of ~$1.5B. The companies will develop therapies for up to eleven target protein in multiple therapeutic areas The agreement involves the collaboration of a scientific team of both the companies, […]Read More

Alexion Enters into an Exclusive License Agreement with Eidos to

Shots: Eidos to receive $25M upfront, $25 equity investment at a premium to the market price upon deal execution, milestone and royalties. Alexion to get an exclusive license to develop & commercialize AG10 in Japan The focus of the agreement is to expand Alexion’s amyloidosis portfolio with the addition of Eidos’ AG10 for patients with […]Read More

Novartis Signs an Exclusive Research and Option to Acquire Agreement

Shots: Novartis to get an option to acquire IFM Due (a subsidiary of IFM Therapeutics) in exchange of funding for research & development of cGAS/STING program. Post exercising of option, IFM to receive $840M including up front and other contingent consideration IFM has two preclinical pipeline programs, first developing as oral STING antagonist having the […]Read More

Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to

Shots: Lupin to receive $20M up front, ~$700M as clinical, regulatory & commercial milestones with royalties on sales of the product. Boehringer Ingelheim to get right to utilize Lupin’s LNP3794 in combination with its KRAS inhibitors for patients with gastrointestinal and lung cancers harboring KRAS mutations The focus of the agreement is to robust Boehringer’s […]Read More

Celltrion Enters into a Contract to Manufacture Agreement for its

Shots: Celltrion has picked to manufacture its biosimilar Remsima’s drug substance at Lonza’s Singapore facility to supply it in American and European markets following its approval in the EU and the US The focus of the agreement is to diversify Celltrion’s biosimilar supply base and meet the increasing demands of the biosimilar market. In H1’19, […]Read More